JOHN E. MAJOR, CHAIRMANChairman of the Board
Broadcom, Inc.
Mr. Major is the non-executive chairman of the board of Broadcom, Inc., a
major technology innovator and global leader in semiconductors for
wired and wireless communications. He is founder and president of MTSG, a
private investment, consulting and governance company.
Mr. Major has also held Chief Executive positions at Novatel Wireless, Inc., a wireless data access solutions company and Wireless Knowledge, a San Diego-based joint venture between Microsoft Corporation
and QUALCOMM. Prior to joining Wireless Knowledge in 1998, Mr. Major
served as corporate executive vice president of QUALCOMM and president
of its Wireless Infrastructure Division. He is currently on the boards
of Littelfuse, Orbcomm and Lennox Corporations.
Mr. Major participates in several industry, research and educational
organizations and is currently chairman of CommNexus-a nonprofit
organization created to support the growth and success of the San Diego
area communications industry. He is chairman of the University of
Illinois Chicago Engineering School Advisory Board, on the boards of the
Rancho Santa Fe Foundation and the University of Rochester Hajim School
of Engineering and Applied Science Dean's Advisory Committee.
He has a B.S. in Mechanical and Aerospace Engineering from the University
of Rochester, and an M.S. in Mechanical Engineering from the University of
Illinois. He holds an M.B.A. with Distinction from Northwestern
University Kellogg School and a J.D. from Loyola University. He received
an honorary doctorate from Westminster College. In 2002, he received
the Meliora Citation for Career Achievement from the University of
Rochester. He holds 10 US patents.
DAVID DOMINGUEZChief Executive Officer
The Andrew Lauren Company
Mr. Dominguez has a long professional history as a successful entrepreneur. He has engaged in a broad array of fields and businesses for more than three decades. Since 1975 Mr. Dominguez has served as chairman, president, managing partner and/or CEO of numerous companies. They include EarthCraft, a chain of retail stores; Saunders Telecom, a manufacturer of telecom infrastructure hardware; Polo Players d.b.a. the Polo Ralph Lauren Shops, a chain of retail stores in California, Arizona and Hawaii; Standards of Excellence, distributor of high end appliances and plumbing fixtures; Central Wholesale Plumbing and Supply; Partner Press, commercial printing; and AdDnamix, an internet advertising company. Currently, Mr. Dominguez is CEO of The Andrew Lauren Companies and a partner in Alta Information Services.
Mr. Dominguez has also served on numerous boards including Independence One Bank. He has been involved in a variety of community organization boards, of which include: the Salvation Army, the Village Church Foundation and Boy Scouts of America. Mr. Dominguez also served as Chairman of the San Diego Young Presidents Organization, and Chairman of the World Presidents Organization. Currently, Mr. Dominguez serves the Village Church Foundation, San Diego YMCA, and is Chairman of Freedom is Not Free-a non-partisan non-profit organization established with the mission of: aiding wounded troops, their families and the families of the fatally wounded.
ROBERT C. DYNES, Ph.D.
President Emeritus, University of California
Former Chancellor, UC San Diego
Dr. Dynes, a distinguished physicist, was the 18th president of the University of California system-serving for five years from 2003 to 2008 and subsequently named UC president emeritus. Prior to assuming the UC president role, Dr. Dynes served as the sixth chancellor of UC San Diego from 1996 to 2003. He came to UC San Diego in 1990 after a 22-year career at AT&T Bell Laboratories, where he was department head of semiconductor and material physics research and director of chemical physics research. Dr. Dynes recently rejoined the UC San Diego faculty as a professor in the Department of Physics.
Over the years, Dr. Dynes has received numerous scientific awards. In 1989, he was elected to the National Academy of Sciences; in 1990, he received the Fritz London Award in Low Temperature Physics; and in 1994 he was elected to the American Academy of Arts and Sciences. Since leaving the UC presidency in June 2008, Dr. Dynes joined the boards of the San Diego Foundation, the Argonne National Laboratory, the Canadian Foundation for Innovation review panel, and the Helmholtz Foundation in Germany. He recently chaired a National Academy of Sciences Study Committee on Advanced Radiation Detection for the Department of Homeland Security.
Dr. Dynes has also served on the executive committee of the U.S. Council on Competitiveness, the California Commission for Jobs and Economic Growth and is a Fellow of the California Council on Science and Technology.
MARK FISCHER
President
Sullivan Moving and Storage Company
Mr. Fischer is the President and owner of Sullivan Moving and Storage Company (Sullivan) headquartered in San Diego. Sullivan is the largest United Van Lines agent in San Diego County and currently has three full service locations in San Diego, Vista, CA and Phoenix, AZ as well as a military only agency and two special product distribution centers. Sullivan is a shareholder in UniGroup, Inc. UniGroup is a holding company that owns United Van Lines, Mayflower Van Lines, an insurance company and a truck leasing company with consolidated revenues of over $2 billion. UniGroup is ranked as one of the largest privately held companies in the United States and is owned exclusively by its operating agents. UniGroup has 1100 locations in more than 100 countries. Sullivan provides domestic and international relocation services for thousands of employees with many well-known companies each year.
Mr. Fischer joined Sullivan Moving and Storage in June of 1978 as its Controller. In 1982, Mr. Fischer was named general manager of Sullivan and in 1987 became the President and sole owner.
Sullivan has been involved with multiple functions for Rady Children's Hospital for the last 15 years. Sullivan is listed as a Miracle Maker and a Friend of the Hospital and is a major sponsor every year for their Celebration of Champions.
Sullivan has been an advocate and supporter of the National Multiple Sclerosis Society in San Diego for the past 20 years, providing trucking and warehousing services for their annual walk, bay-to-bay bike tour, and dinner charity auction. Sullivan was recently nominated as the Corporate Partner Volunteer of the Year for 2010 by the Pacific South Coast Chapter of the Multiple Sclerosis Society.
Mr. Fischer has a B.S. in accounting from Colorado State University.
LEROY HOOD, M.D., Ph.D.
Co-Founder and President
Institute for Systems Biology, Seattle, Washington
Dr. Hood began his career as a senior scientist at NCI and NIH and then spent 22 years as a Biology Professor at Caltech. His research has focused on fundamental biology (immunity, evolution, genomics) and engineering biology-developing five instruments for deciphering various types of biological information (DNA, RNA, proteins and systems). During the 1990s and early 2000s, his DNA sequencer revolutionized genomics, allowing the rapid automated sequencing of DNA and the successful mapping of the human genome. In 2000, he co-founded the Institute for Systems Biology where he applied these technologies to diverse fields including immunology, neurobiology, cancer biology, molecular evolution and systems medicine.
Dr. Hood is one of only seven scientists (of more than 6000 members) elected to all three National Academies: Sciences, Engineering and Health. He has received many prestigious awards including: the 1987 Lasker Prize for his studies on the mechanism of immune diversity; 2002 Kyoto Prize in Advanced Technology; 2003 Lemelson-MIT Prize for Innovation and Invention; 2003 Association for Molecular Pathology (AMP) Award for Excellence in Molecular Diagnostics; 2004 Biotechnology Heritage Award; and the 2006 Heinz Award in Technology, the Economy and Employment. In 2007, he was elected to the Inventors Hall of Fame (for the automated DNA sequencer). And in 2008, he received the Pittcon Heritage Award for helping transform the biotech industry.
Dr. Hood founded or co-founded more than 14 biotechnology companies, including: Amgen, Applied Biosystems, Systemix, Darwin, Rosetta, and most recently Integrated Diagnostics-where he is pioneering systems medicine and the systems approach to disease. He has published more than 650 peer-reviewed papers, received 15 patents, co-authored textbooks in biochemistry, immunology, molecular biology, systems biology and genetics. In 1992, Dr. Hood co-authored The Code of Codes with Dan Keveles, a popular book on the human genome project.
RICHARD K. KORNFELD
Chief Executive Officer
Grid2Home
Mr. Kornfeld has worked for some of the region's most notable tech companies, including Linkabit, Qualcomm and Texas Instruments. Currently serving as CEO for Grid2Home, Mr. Kornfeld was also most recently EVP & Chief Strategy Officer, NextWave Wireless and NextWave Broadband and previous to that served as President & CEO, Staccato Communications from 2004 to 2006.
Prior to taking the helm of Staccato, Mr. Kornfeld was vice president and general manager of Texas Instruments' Wireless Chipset Business Unit. He joined TI as part of the acquisition of Dot Wireless, where he was co-founder, chairman, and CEO. Prior to founding Dot Wireless, Mr. Kornfeld was a founding member of NextWave Telecom, Inc., where he was the senior vice president and general manager of the Consumer Products division. Previously, Mr. Kornfeld was vice president of engineering at Qualcomm, leading the development of the first commercial CDMA subscriber equipment. Prior to joining Qualcomm, Mr. Kornfeld held technical positions at M/A-Com Linkabit.
Mr. Kornfeld received his B.S. from the University of California, San Diego where he was also named the Alumni of the Year in 2001. He serves on the Council of Advisors of UCSD's Jacobs School of Engineering.
MITCHELL KRONENBERG, Ph.D.
President & Chief Scientific Officer
La Jolla Institute for Allergy & Immunology
Dr. Kronenberg was appointed President of La Jolla Institute for Allergy & Immunology in September 2003. He is responsible for the overall administration of physical resources, finances and space at the Institute, and works with the Institute's board of directors, faculty, and executive management to develop and implement strategic plans for shaping the Institute's future.
In addition to his duties as LIAI's chief executive officer, Dr. Kronenberg serves as Chief Scientific Officer of the Institute and Head of the Division of Developmental Immunology. He conducts an active research program on the development of the immune system and the pathogenesis of autoimmune disease, and is a world-renowned expert in the field of mucosal and innate immunity.
Dr. Kronenberg graduated with a bachelor's degree in biochemistry from Columbia University, and earned his Ph.D. from the California Institute of Technology (Caltech) in 1983. He stayed on at Caltech as a postdoctoral fellow, and joined the faculty of the UCLA School of Medicine in 1986, serving first as Assistant, and later as Associate and full Professor. In 1997, he moved to La Jolla Institute for Allergy & Immunology
to head the Division of Developmental Immunology. He also is an Adjunct Professor of Biology at the University of California, San Diego.
Dr. Kronenberg is the co-author of more than 225 scientific publications, and according to the Institute for Scientific Information, he is one of the most highly cited scientists in the field of immunology. Dr. Kronenberg has been consistently well funded by the National Institutes of Health (NIH) for more than 20 years, and currently is the principal investigator on five NIH research grants, including an NIH MERIT award. He has been on a number of grant review panels for NIH and private medical research agencies, and has served or is serving on the editorial board of seven scientific journals. He is the winner of the Richard Dwyer award for cancer research (UCLA) and has been the Kroc Professor of Medicine at the University of California, Davis, and the Wellcome Foundation visiting Professor at Harvard University.
MICHAEL J. MARTINPresident & Chief Executive Officer
RainTree Oncology Services Corporation
In January 2011, Mr. Martin founded RainTree Oncology Services Corporation, a comprehensive, fully integrated oncology services company, for which he serves as President and Chief Executive Officer.
Previous to starting RainTree, from 2009-2010, Mr. Martin was President of Waveland Capital Group LLC where he led Waveland's comprehensive suite of corporate financial services. Prior to joining Waveland, from 2005-2009 Mr. Martin was President of the International Oncology Network (ION)-the oncology division of AmerisourceBergan Corporation (ABSG), a "Fortune 27" company. Mr. Martin was instrumental in strengthening the division's core competency as the premier group purchasing organization in the nation, while simultaneously expanding its reach in the oncology marketplace as a complete physicians services organization. Additionally, under Mr. Martin's leadership, the division developed and implemented a network-wide data aggregation initiative that focused on therapy compliance and increased practice efficiently, which ultimately lead to improved patient care.
Prior to ABSG, Mr. Martin's experience in health care, medical systems, group purchasing organizations and services solutions created a strong underpinning of business excellence which he has carried throughout his career. Mr. Martin's leadership and organizational background spans more than 25 years and includes executive management roles at Tensys Medical, Medibuy, Premier Inc. and GE Medical Systems.
Mr. Martin received his B.A. from West Liberty State College in West Virginia and serves or has served on the Board of Directors of Tensys Medical, Crossflo Systems and Waveland portfolio company Vesta Medical, LLC.
TOSHIFUMI MIKAYAMA, Ph.D.
Managing Officer,
Director, Corporate Strategy & Planning Department
Kyowa Hakko Kirin Co., Ltd., Japan
Dr. Mikayama is Managing Officer, Director, Corporate Strategy & Planning Department at Kyowa Hakko Kirin Co., Ltd.
He joined Kirin Applied Bioscience Lab in 1983 as a Research Scientist,
and became Manager of the Pharmaceutical Research Laboratory in 1994.
One of Kirin's three primary pharmaceutical interests is in immune
system diseases, focusing specifically on the development of advanced
pharmaceutical products involving human antibodies and cell therapy.
Dr. Mikayama received his B.S., M.S. and Ph.D. degrees in Biophysics
and Biochemistry from Tokyo University, Japan. He served as Senior Vice President and Chief Scientific Officer for
Gemini Science Inc. (now Kyowa Hakko Kirin California Co., Ltd.) from 1998 to 2002, and
then served as Vice President and Scientific Director for Pharmaceutical Division, Kirin Brewery
Co. Ltd. in Gunma, Japan.
RHONDA RHYNE
Chairman, Chief Executive Officer
Association for Innovative Cardiovascular Advancements
Ms. Rhyne has more than 25 years experience in health care with both public and private industry companies, as well as experience as a clinical pharmacist. She moved to San Diego in 1995, when she was recruited to serve as President of CardioDynamics, a cardiovascular medical technology company. She led CardioDynamics' dramatic rise from a small startup to a multi-million dollar organization, which was acquired by SonoSite, Inc. in 2009.
Prior to joining CardioDynamics, Ms. Rhyne held positions of Chief Executive Officer and Board Director at Culture Technology, Inc., a privately-held biotechnology company specializing in culturing autologous skin for burn patients.
Currently, she serves as Chairman and CEO of the Association for Innovative Cardiovascular Advancements, whose mission is to enhance the lives of cardiovascular patients by fostering research and education of innovative cardiovascular technologies.
Ms. Rhyne earned an M.B.A. from the UCLA Anderson School of Business Administration and a B.S. in Pharmacy from Washington State University. She currently sits on the Board of Directors for Athena San Diego, a nonprofit organization for executive women, and on the Dean's Advisory Council for Washington State University's College of Pharmacy. Ms. Rhyne has received several awards over the years, including Ernst and Young's Entrepreneur of the Year award in Medical Products in 2003, and the San Diego Business Journal Women Who Mean Business Award in 2005.
WILLIAM R. "BILL" ROHN
Former Chief Operating Officer
Biogen Idec, Inc.
Mr. Rohn has more than 30 years of management experience in the biotechnology and pharmaceutical industry, including more than 10 years in executive leadership positions at IDEC Pharmaceuticals and Biogen Idec, a $4 billion Fortune 500 company and leading global biotech, where he served as Chief Operating Officer until his retirement in 2005.
He joined IDEC in 1993 as Senior Vice President, Commercial and Corporate Development, was appointed Senior Vice President, Commercial Operations and was promoted to Chief Operating Officer in 1998. He was responsible for building IDEC's commercial infrastructure to support the 1997 launch of Rituxan®, the first monoclonal antibody approved in the U.S. for the treatment of cancer. In 2002, Mr. Rohn became IDEC's President, responsible for sales, marketing, business development, manufacturing, quality, medical affairs and CMC regulatory affairs. The following year Biogen and IDEC merged, becoming the third-largest biotechnology company in the world.
Mr. Rohn received his B.A. from Michigan State University and currently serves on the Boards of Directors of three biotechnology companies: Intellikine, Inc., Cerus Corporation, and Cebix, Inc. Most recently, he also served on the Board of Elan Corporation, plc., a neuroscience-based biotechnology company, and Metabasis Therapeutics, Inc. a San Diego-based biopharmaceutical company acquired by Ligand Pharmaceuticals in early 2010.
SAMUEL STROBER, M.D.
Professor of Medicine, Division of Immunology and Rheumatology
Stanford University School of Medicine
Dr. Strober has served as Professor of Medicine at Stanford University
School of Medicine, Division of Immunology and Rheumatology, since 1982.
He held the position of Chief of that Division from 1978 to 1997,
having first arrived at the School of Medicine as a Senior Assistant
Resident in 1970. He has been President of the Clinical Immunology
Society, and is a founder of two biotechnology companies (Dendreon, Inc.
and Innate Immune, Inc.)
Dr. Strober's laboratory research and clinical trials have focused on
the immune cell interactions that prevent graft versus host disease and
retain graft anti-tumor activity after bone marrow transplantation, as
well as cell interactions that prevent rejection of organ transplants in
the absence of immunosuppressive drugs. He is also interested in the
pathogenesis of systemic lupus erythematosus, a disease in which the
immune system causes excessive inflammation leading to the damage of
multiple organs. Throughout his career, Dr. Strober has published over
300 peer-reviewed articles in scientific journals, and has served on
editorial boards of immunology journals. He received the Leon Reznick
Memorial Prize from the Harvard Medical School.
Dr. Strober received his B.A. from Columbia University and his M.D. from
Harvard University. He completed fellowships in the Surgical Research
Laboratory at the Peter Bent Brigham Hospital in Boston, and in the Sir
William Dunn School of Pathology in Oxford University followed by an
internship in medicine at Massachusetts General Hospital. Prior to
joining Stanford, Dr. Strober completed additional postdoctoral training
as a Research Associate in the Laboratory of Cell Biology of the
National Cancer Institute, Bethesda.
DAVID R. WEBB, Ph.D.
Adjunct Professor, Department of Molecular Biology
The Scripps Research Institute
Dr. Webb became Adjunct Professor, Department of Molecular Biology at The Scripps Research Institute upon his retirement from Celgene-San Diego in June 2011.
Dr. Webb joined Celgene-San Diego in 2003 as Vice President, Research. During this time, the Research Division placed six drugs into clinical development; four of which are still in clinical studies (Phases I and II) in the areas of cancer and inflammation/autoimmunity (one with Array Biopharma). Between 1995 and 2003, he held a series of senior management positions in several biotechnology companies where he developed and led drug discovery programs focused on inflammation, asthma, cancer and diabetes. These include Syrrx, OSI Pharmaceuticals, and Cadus Pharmaceutical Corporation where he was Vice President of Research and Chief Scientific Officer from 1995 to 1999 and adjunct professor of Microbiology and Immunology at New York Medical College. From 1987 to 1995, Dr. Webb was at Syntex, Inc. where he held the positions of Distinguished Scientist and later, Director, Institute of Immunology and Biological Sciences and was also a Consulting Professor of Cancer Biology at Stanford University. From 1973 to 1987, he was a member of the Department of Cell Biology, Roche Institute of Molecular Biology and Adjunct Associate Professor at Columbia University, College of Physicians and Surgeons.
Dr. Webb earned his Ph.D. in Microbiology/Immunology at Rutgers, The State University of New Jersey-New Brunswick, and a B.A., M.A. in Biology from California State University-Fullerton.
